Business & Industry

Gilead Sciences has added another synthetic lethal asset to its oncology portfolio, agreeing to pay $80 million upfront to obtain global rights to a clinic-ready cancer therapy from China-based Genhouse Bio. Headquartered in Suzhou, Genhouse Bio has been advancing its...

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive...

The rise of smart factories in the pharmaceutical sector is characterized by the integration of AI, IoT, and real-time analytics to create highly efficient production ecosystems.

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Adopting green hydrogen as a primary energy source in pharmaceutical facilities offers a pathway to deep decarbonization, sustainable process heating, and cleaner manufacturing.

Novartis has started work on a $1.1 billion biomedical research facility in California, adding a major new pillar to its long-term US investment strategy. The San Diego biomedical R&D site is part of a wider $23 billion expansion programme...

Bristol Myers Squibb has entered a global agreement with Evinova to deploy AI-powered clinical development tools across its worldwide pipeline. The Bristol Myers Evinova partnership is designed to improve trial efficiency, reduce costs and support better decision-making throughout drug...